MAP3K9
MOLECULAR TARGETmitogen-activated protein kinase kinase kinase 9
MAP3K9 (mitogen-activated protein kinase kinase kinase 9) is targeted by 28 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting MAP3K9
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | alvocidib | 4.52 | 91 |
| 2 | foretinib | 4.34 | 76 |
| 3 | tozasertib | 4.33 | 75 |
| 4 | bosutinib | 4.08 | 58 |
| 5 | midostaurin | 3.85 | 46 |
| 6 | brigatinib | 3.81 | 44 |
| 7 | pazopanib | 3.69 | 39 |
| 8 | neratinib | 3.66 | 38 |
| 9 | nintedanib | 3.61 | 36 |
| 10 | tae 684 | 3.43 | 30 |
| 11 | fedratinib | 3.40 | 29 |
| 12 | dovitinib | 3.09 | 21 |
| 13 | jnj 7706621 | 3.09 | 21 |
| 14 | lestaurtinib | 3.04 | 20 |
| 15 | ruboxistaurin | 2.94 | 18 |
| 16 | r 406 | 2.83 | 16 |
| 17 | staurosporinone | 2.77 | 15 |
| 18 | apitolisib | 2.71 | 14 |
| 19 | kw 2449 | 2.64 | 13 |
| 20 | atuveciclib | 2.56 | 12 |
| 21 | defactinib | 2.48 | 11 |
| 22 | gsk 461364 | 2.40 | 10 |
| 23 | berzosertib | 2.30 | 9 |
| 24 | su 014813 | 2.20 | 8 |
| 25 | rebastinib | 2.20 | 8 |
| 26 | cep 1347 | 2.08 | 7 |
| 27 | cerdulatinib | 1.95 | 6 |
| 28 | Axitinib | 0.69 | 1 |
About MAP3K9 as a Drug Target
MAP3K9 (mitogen-activated protein kinase kinase kinase 9) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 28 compounds with documented MAP3K9 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
MAP3K9 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.